NBIO (Nascent Biotech) Median PS Value: $0.00 (As of Jun. 30, 2026)


What is Nascent Biotech Median PS Value?

Nascent Biotech NBIO +66.67% Median PS Value is $0.00 as of Jun. 30, 2026.

This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Nascent Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0. Nascent Biotech's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2026-06-30), Nascent Biotech's share price is $0.0005. Nascent Biotech's Median PS Value is $0.00. Therefore, Nascent Biotech's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Nascent Biotech's Median PS Value or its related term are showing as below:

NBIO's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.63
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Nascent Biotech  (OTCPK:NBIO) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Nascent Biotech's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.0005/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Biotech Median PS Value Related Terms

Nascent Biotech Median PS Value Historical Data

* Premium members only.

The historical data trend for Nascent Biotech's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Biotech Median PS Value Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Median PS Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nascent Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NBIO vs BTAX, PXMD, XSNX: Median PS Value Comparison

For the Biotechnology subindustry, Nascent Biotech's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nascent Biotech Price-to-Median-PS-Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's Price-to-Median-PS-Value falls into.


Nascent Biotech Median PS Value Calculation

Nascent Biotech's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
Nascent Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Median PS Value →
What does a Median PS Value of $0.00 mean?
Nascent Biotech (NBIO) has a Median PS Value of $0.00 as of Jun. 30, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Nascent Biotech and its competitors.
Is Nascent Biotech's Median PS Value too high?
Nascent Biotech's current Median PS Value is $0.00.
How does Nascent Biotech's Median PS Value compare to BTAX and PXMD?
Nascent Biotech's Median PS Value of $0.00 can be compared against companies in the Biotechnology industry. The industry median Median PS Value is 0.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 276 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Nascent Biotech and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nascent Biotech's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Biotech stock overvalued right now?
Nascent Biotech (NBIO) has a current Median PS Value of $0.00. The current Median PS Value is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Nascent Biotech (NBIO), the current Median PS Value is $0.00 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Biotech Business Description

Address 631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.